Literature DB >> 23205100

Study of the correlation between H-ras mutation and primary hepatocellular carcinoma.

Guode Sui1, Xuexiao Ma, Shiguo Liu, Haitao Niu, Qian Dong.   

Abstract

The aim of this study was to investigate the correlation between H-ras mutation and primary hepatocellular carcinoma (HCC) and to describe the role of H-ras mutation in carcinogenesis. Clinical samples of 69 patients were collected and the expression levels of H-ras in HCC and the surrounding normal tissues were examined using HotStarTaq PCR. H-ras mutation was further analyzed using the PCR direct sequencing method. The results showed that H-ras mutation was present in 49 samples (49/69, 71.01%), of which 19 had codon 40 mutated from CTA to CTG and 30 had codon 61 mutated from GGC to AGC. By contrast, only 2 mutations were found in the normal tumor-adjacent tissues. The H-ras mutation rate in the high-risk of metastatic recurrence group was markedly higher than that in the low-risk group (P<0.01). The H-ras mutation rate in patients with metastatic recurrence during postoperative follow-up was also significantly higher than that in patients without metastatic recurrence (P<0.01). Based on the above results, the H-ras mutation frequency in cancer tissues is markedly higher compared with that in normal tissues. H-ras mutation may play an important role in the genesis and development of HCC and may serve as a reliable marker for individual comprehensive therapy in HCC.

Entities:  

Year:  2012        PMID: 23205100      PMCID: PMC3506700          DOI: 10.3892/ol.2012.832

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  15 in total

1.  Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma.

Authors:  Qiang Zuo; Hui Huang; Min Shi; Futing Zhang; Jiping Sun; Jianping Bin; Yulin Liao; Wangjun Liao
Journal:  Anat Rec (Hoboken)       Date:  2011-12-20       Impact factor: 2.064

2.  Analysis of binding site hot spots on the surface of Ras GTPase.

Authors:  Greg Buhrman; Casey O'Connor; Brandon Zerbe; Bradley M Kearney; Raeanne Napoleon; Elizaveta A Kovrigina; Sandor Vajda; Dima Kozakov; Evgenii L Kovrigin; Carla Mattos
Journal:  J Mol Biol       Date:  2011-09-16       Impact factor: 5.469

3.  Transforming growth factor-β-stimulated clone-22 is a negative-feedback regulator of Ras / Raf signaling: Implications for tumorigenesis.

Authors:  Masaki Nakamura; Jiro Kitaura; Yutaka Enomoto; Yang Lu; Koutarou Nishimura; Masamichi Isobe; Katsutoshi Ozaki; Yukiko Komeno; Fumio Nakahara; Toshihiko Oki; Haruki Kume; Yukio Homma; Toshio Kitamura
Journal:  Cancer Sci       Date:  2011-11-01       Impact factor: 6.716

4.  H-ras consensus sequence and mutations in primary hepatocellular carcinomas of lemurs and lorises.

Authors:  J M Cullen; C Williams; L Zadrozny; J T Otstot; G G Solomon; R C Sills; H-H L Hong
Journal:  Vet Pathol       Date:  2010-12-01       Impact factor: 2.221

5.  Transforming growth factor-β enhances invasion and metastasis in Ras-transfected human malignant epidermal keratinocytes.

Authors:  Maria Davies; Stephen S Prime; John W Eveson; Nicky Price; Anu Ganapathy; Anita D'Mello; Ian C Paterson
Journal:  Int J Exp Pathol       Date:  2012-04       Impact factor: 1.925

Review 6.  Recurrence and metastasis of hepatocellular carcinoma: progress and prospects.

Authors:  Xin-Da Zhou
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2002-02

7.  Differential physiological effects of Raf-1 kinase pathways linked to protein kinase C activation depending on the stimulus in v-H-ras-transformed cells.

Authors:  Michael Lee
Journal:  Cancer Res Treat       Date:  2008-06-30       Impact factor: 4.679

Review 8.  Death pathways triggered by activated Ras in cancer cells.

Authors:  Jean H Overmeyer; William A Maltese
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

Review 9.  Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.

Authors:  Hui-Wen Lo
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

10.  BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases.

Authors:  M J Hoenerhoff; I Chu; D Barkan; Z-y Liu; S Datta; G P Dimri; J E Green
Journal:  Oncogene       Date:  2009-06-22       Impact factor: 9.867

View more
  5 in total

1.  Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features.

Authors:  Dragana Kopanja; Akshay Pandey; Megan Kiefer; Zebin Wang; Neha Chandan; Janai R Carr; Roberta Franks; Dae-Yeul Yu; Grace Guzman; Ajay Maker; Pradip Raychaudhuri
Journal:  J Hepatol       Date:  2015-03-28       Impact factor: 25.083

2.  p19Arf inhibits aggressive progression of H-ras-driven hepatocellular carcinoma.

Authors:  Dragana Kopanja; Shuo Huang; Mohamed Rizwan Haroon Al Raheed; Grace Guzman; Pradip Raychaudhuri
Journal:  Carcinogenesis       Date:  2018-03-08       Impact factor: 4.944

3.  Targeting the effect of sofosbuvir on selective oncogenes expression level of hepatocellular carcinoma Ras/Raf/MEK/ERK pathway in Huh7 cell line.

Authors:  Muhammad Atif; Muhammad Abdul Mustaan; Sadia Falak; Abdul Ghaffar; Bushra Munir
Journal:  Saudi J Biol Sci       Date:  2022-06-01       Impact factor: 4.052

4.  Peroxiredoxin I is important for cancer-cell survival in Ras-induced hepatic tumorigenesis.

Authors:  Bing Han; Hye-Jun Shin; In Seon Bak; Yesol Bak; Ye-Lin Jeong; Taeho Kwon; Young-Ho Park; Hu-Nan Sun; Cheol-Hee Kim; Dae-Yeul Yu
Journal:  Oncotarget       Date:  2016-10-18

5.  Proteomic analysis revealed common, unique and systemic signatures in gender-dependent hepatocarcinogenesis.

Authors:  Huiling Li; Zhuona Rong; Hong Wang; Nan Zhang; Chunwen Pu; Yi Zhao; Xu Zheng; Chuanyi Lei; Yang Liu; Xiaoqin Luo; Jun Chen; Fujin Wang; Aiguo Wang; Jingyu Wang
Journal:  Biol Sex Differ       Date:  2020-08-13       Impact factor: 5.027

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.